Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ModuLung
2014-004095-31Phase 2Completed
- Sponsor
- Freistaat Bayer respresented by University of Regensburg represented by Kaufmännischer Direktor
- Start
- May 2015
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of treosulfan, pioglitazone, clarithromycin and nivolumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Freistaat Bayer respresented by University of Regensburg represented by Kaufmännischer Direktor. Primary endpoint: progression-free survival. Started May 2015; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2014-004095-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004095-31.